Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion. A key reason for this activity is the ...

Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

Short interest data from late May indicates varying investor feelings in the healthcare sector, with strong bearish bets ...

The market is up 1.2% over the last week, and in the past year, it has climbed an impressive 27%, with earnings expected to grow by 17% per annum. Though the term 'penny stock' might sound like a ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare.

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The biotechnology industry is defined by its ...

In this article, we will take a look at the 10 Most Profitable Biotech Stocks to Buy Now. Following a turbulent year for the markets in general and biotech in particular, the industry made a notable ...

Biotech stocks are attracting investors as M&A activity, valuations and upcoming catalysts help drive sector momentum.